Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022
August 01, 2022 08:00 ET
|
Portage Biotech, Inc.
--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage...
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
July 20, 2022 09:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival...
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
July 06, 2022 16:05 ET
|
Portage Biotech, Inc.
Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and...
Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study
June 06, 2022 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., June 06, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival...
Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
April 25, 2022 08:00 ET
|
Portage Biotech, Inc.
Collaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for cancer vaccines Portage and NCI will develop agents to enhance the efficacy of...
Portage Biotech Provides Update on Clinical-Stage and Development Programs
March 31, 2022 08:00 ET
|
Portage Biotech, Inc.
Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development Company continues to work toward multiple clinical readouts in 2022 ...
Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting
March 09, 2022 09:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., March 09, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient...
Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year
February 24, 2022 17:43 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient...
Portage Biotech Announces New Appointments to its Management Team and Board of Directors
February 15, 2022 08:00 ET
|
Portage Biotech, Inc.
Leading biopharma executive Brian Wiley joins as Chief Business Officer Experienced financial consultant Joseph Ciaverella advances to new role as Chief Accounting Officer Jim Mellon, Linda Kozick...
Portage Biotech Announces Participation in January 2022 Investor Conferences
January 05, 2022 08:00 ET
|
Portage Biotech, Inc.
WESTPORT, Conn., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient...